A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results.

Steven AttiaVanessa BolejackKristen N GanjooSuzanne GeorgeMark AgulnikDaniel RushingElizabeth T LoggersMichael B LivingstonJennifer WrightSant P ChawlaScott H OkunoDenise K ReinkeRichard F RiedelLara E DavisChristopher W RyanRobert G Maki

Published in: Cancer medicine (2022)

Regorafenib has modest activity in the Ewing family sarcomas. Toxicity was similar to that seen in approval studies.

Keyphrases

soft tissue
metastatic colorectal cancer
phase iii
open label
study protocol
clinical trial
phase ii
high grade
oxidative stress
bone mineral density
case control
randomized controlled trial
drug administration
bone loss
bone regeneration